{"id":47048,"date":"2025-01-29T08:11:41","date_gmt":"2025-01-29T08:11:41","guid":{"rendered":"https:\/\/my.legal500.com\/developments\/?post_type=press_releases&#038;p=47048"},"modified":"2025-01-29T08:11:50","modified_gmt":"2025-01-29T08:11:50","slug":"homburger-advises-bioversys-ag-on-its-ipo-on-six-swiss-exchange","status":"publish","type":"press_releases","link":"https:\/\/my.legal500.com\/developments\/press-releases\/homburger-advises-bioversys-ag-on-its-ipo-on-six-swiss-exchange\/","title":{"rendered":"Homburger advises BioVersys AG on its IPO on SIX Swiss Exchange"},"content":{"rendered":"<p><strong>On January 29, 2025, BioVersys AG, a clinical-stage biopharmaceutical company developing and commercializing novel antibacterial products for life-threatening infections domiciled in Basel, Switzerland,<\/strong> <!--more-->announced the launch of its Initial Public Offering (IPO) on SIX Swiss Exchange, the publication of the offer price and the start of the bookbuilding process. The IPO comprises a primary offering targeting gross proceeds of CHF 80 m (including an over-allotment option targeting gross proceeds of CHF 5 m). The implied market capitalization of the company, assuming all offered shares are sold in the IPO and the over-allotment option is exercised in full, is approximately CHF 212.9 m. The first day of trading is expected to be February 7, 2025.<\/p>\n<p>BioVersys focuses on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The Company&#8217;s most advanced R&amp;D programs address nosocomial pneumonia and blood stream infections caused by <em>Acinetobacter baumannii<\/em> (BV100, phase 3-ready) and tuberculosis (alpibectir, phase 2a). In addition to its domicile in the biotech hub in Basel, Switzerland, BioVersys has operations in in Lille, France, Delaware, United States and Guangzhou, China.<\/p>\n<p>Citigroup Global Markets Limited, UBS AG and Stifel Europe AG are acting as Joint Global Coordinators and Joint Bookrunners on the IPO, Mirabaud &amp; Cie SA and Octavian AG as Selling Agents.<\/p>\n<p>Homburger is advising BioVersys on all aspects of the IPO as lead counsel. The Homburger team is co-led by Dieter Gericke and Lorenzo Togni and includes Thierry Burckhardt, Magda Aref, Simone Schmid, Raphael Linder, Harun Cetin and Leander Etter (all Corporate \/ M&amp;A and Capital Markets). Luca Dal Molin and Kristina Martinovic (both IP \/ IT) are providing intellectual property advice, Jeremy Reichlin (Employment and Executive Compensation) is providing employment and executive compensation advice, and Reto Heuberger and Philippe Weber (both Tax) are providing tax advice.<\/p>\n<hr \/>\n<p>&nbsp;<\/p>\n","protected":false},"featured_media":0,"template":"","class_list":["post-47048","press_releases","type-press_releases","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/my.legal500.com\/developments\/wp-json\/wp\/v2\/press_releases\/47048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/my.legal500.com\/developments\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/my.legal500.com\/developments\/wp-json\/wp\/v2\/types\/press_releases"}],"wp:attachment":[{"href":"https:\/\/my.legal500.com\/developments\/wp-json\/wp\/v2\/media?parent=47048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}